[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Caredx Inc (CDNA)

Caredx Inc (CDNA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,087,315
  • Shares Outstanding, K 51,216
  • Annual Sales, $ 379,810 K
  • Annual Income, $ -21,350 K
  • EBIT $ -31 M
  • EBITDA $ -9 M
  • 60-Month Beta 2.54
  • Price/Sales 2.71
  • Price/Cash Flow 3,167.32
  • Price/Book 3.50

Options Overview Details

View History
  • Implied Volatility 86.35% (-8.81%)
  • Historical Volatility 85.64%
  • IV Percentile 33%
  • IV Rank 19.28%
  • IV High 224.22% on 03/10/26
  • IV Low 53.41% on 05/21/25
  • Expected Move (DTE 20) 1.87 (8.81%)
  • Put/Call Vol Ratio 0.24
  • Today's Volume 41
  • Volume Avg (30-Day) 35
  • Put/Call OI Ratio 0.48
  • Today's Open Interest 672
  • Open Int (30-Day) 457
  • Expected Range 19.36 to 23.10

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.11
  • Number of Estimates 1
  • High Estimate $-0.11
  • Low Estimate $-0.11
  • Prior Year $-0.19
  • Growth Rate Est. (year over year) +42.11%

Price Performance

See More
Period Period Low Period High Performance
1-Month
15.56 +36.44%
on 04/10/26
23.24 -8.65%
on 04/17/26
+3.39 (+19.00%)
since 03/24/26
3-Month
15.56 +36.44%
on 04/10/26
23.24 -8.65%
on 04/17/26
+0.81 (+3.97%)
since 01/23/26
52-Week
10.96 +93.70%
on 07/17/25
23.24 -8.65%
on 04/17/26
+2.74 (+14.82%)
since 04/24/25

Most Recent Stories

More News
CareDx Announces Presentation of More Than 50 Abstracts Including 16 Oral Presentations at the International Society for Heart and Lung Transplantation’s 46th Annual Meeting

Breadth of Data Demonstrates the Important Role of Precision Medicine Testing in Post-Transplant Monitoring and Decision Making New SHORE Data Highlights Significance...

CDNA : 21.23 (+5.83%)
CareDx Introduces AlloSeq Nano at EFI 2026, Expanding HLA Typing Portfolio with Long-Read Sequencing

AlloSeq Nano delivers rapid, high‑resolution HLA and ABO genotyping in a single assay through a streamlined, long‑read workflow designed for transplant and donor typing laboratories.

CDNA : 21.23 (+5.83%)
CareDx Announces Agreement to Divest Lab Products Business to EuroBio Scientific for $170 Million and Announces First Quarter Preliminary Financial Results

Transaction Expected to Sharpen CareDx’s Focus on Core Precision Medicine Testing Services and Patient and Digital Solutions, Improve Financial Flexibility, Simplify Operating Model, and Support AEBITDA...

CDNA : 21.23 (+5.83%)
CareDx to Report First Quarter 2026 Financial Results on April 28, 2026

CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare...

CDNA : 21.23 (+5.83%)
CareDx Announces VANTx™, an AI‑Powered Clinical Data & Analytics Platform Built on CareDx’s Proprietary, Large-Scale, Longitudinal Solid Organ Transplant Datasets

First-of-its-kind, cloud-native AI platform for transplant program cohort analysis, clinical research, and real-world evidence generation announced at the 2026 Precision Medicine World Conference

CDNA : 21.23 (+5.83%)
CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CareDx, Inc. (Nasdaq: CDNA), — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value...

CDNA : 21.23 (+5.83%)
CareDx Announces Appointment of Keith Kennedy as Chief Operating Officer and Chief Financial Officer

Kennedy brings seven years of public company CFO experience

CDNA : 21.23 (+5.83%)
CareDx: Q4 Earnings Snapshot

CareDx: Q4 Earnings Snapshot

CDNA : 21.23 (+5.83%)
CareDx Announces Fourth Quarter and Full Year 2025 Financial Results

Full Year 2025 Total Revenue of $380 Million Increased 14% Year-Over-Year Expects Full Year 2026 Revenue of $420 Million to $444 Million

CDNA : 21.23 (+5.83%)
CareDx to Participate in the Raymond James 47th Annual Institutional Investors Conference

CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high‑value healthcare...

CDNA : 21.23 (+5.83%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

CareDx, Inc. is a commercial stage company. It develops, markets, and delivers a diagnostic surveillance solution for heart transplant recipients. The Company provides AlloMap, a noninvasive blood test used to aid in the identification of heart transplant recipients. It is also pursuing other areas of...

See More

Key Turning Points

3rd Resistance Point 23.46
2nd Resistance Point 22.44
1st Resistance Point 21.83
Last Price 21.23
1st Support Level 20.20
2nd Support Level 19.18
3rd Support Level 18.57

See More

52-Week High 23.24
Last Price 21.23
Fibonacci 61.8% 18.55
Fibonacci 50% 17.10
Fibonacci 38.2% 15.65
52-Week Low 10.96

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.